ClinicalTrials.Veeva

Menu

Anti-inflammatory Status in DM2 Treated Patients (INF-DM2-Ther)

U

University of Catanzaro

Status and phase

Unknown
Phase 4

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Metformin / Pioglitazone Pill
Drug: triple therapy
Drug: Metformin / alogliptin Oral Product

Study type

Interventional

Funder types

Other

Identifiers

NCT04392557
Inflammation-DM2

Details and patient eligibility

About

Diabetes mellitus Type 2 (DMT2) - a progressive insulin secretory defect on the background of insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory disease of the arterial wall, in which leukocytes and oxidized lipoproteins accumulate leading to formation of fatty streaks and atherosclerotic plaques. Atherosclerosis accounts for more than 600,000 deaths annually in the U.S. mainly due to acute myocardial infarction and stroke. Pharmacological therapy of DMT2 includes several drugs used as monotherapy, although combination therapy between metfomin plus thiazolidinediones (TZD) and/or dipeptidyl-peptidase 4 inhibitors (DPP4I) plus TDZ, may delay atherosclerosis progression even if the molecular mechanisms are not clear. Even if normoglycemia is achieved, DMT2 patients still displayed a higher risk for developing atherosclerosis suggesting that other mechanisms of the inflammatory status are involved

Full description

Diabetes mellitus Type 2 (DMT2) - a progressive insulin secretory defect on the background of insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory disease of the arterial wall, in which leukocytes and oxidized lipoproteins accumulate leading to formation of fatty streaks and atherosclerotic plaques. Atherosclerosis accounts for more than 600,000 deaths annually in the U.S. mainly due to acute myocardial infarction and stroke. Pharmacological therapy of DMT2 includes several drugs used as monotherapy, although combination therapy between metfomin plus thiazolidinediones (TZD) and/or dipeptidyl-peptidase 4 inhibitors (DPP4I) plus TDZ, may delay atherosclerosis progression even if the molecular mechanisms are not clear . Even if normoglycemia is achieved, DMT2 patients still displayed a higher risk for developing atherosclerosis suggesting that other mechanisms of the inflammatory status are involved

Enrollment

36 estimated patients

Sex

All

Ages

35 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • DMT2 patients were enrolled in presence of

    1. Age >35 and <75 years old
    2. Uncontrolled diabetes during treatment (glycosylated hemoglobin (HbA1c) > 75 mmol/mol )
    3. Combined therapy at least by 6 months.

Exclusion criteria

  1. HbA1c < 75 mmol/mol (9%);
  2. History of drug abuse or alcohol abuse, averaging more than 30 gm/day (3 drinks per day) in the previous 10 years, or history of alcohol intake averaging greater than 10 gm/day (1 drink per day: 7 drinks per week) in the previous one year;
  3. Estimated glomerular filtration rate (GFR) <30 ml/min (according to MDRD formula)
  4. .Liver Failure
  5. Recent history of Heart stroke, systemic infections, dehydration, lactic acidosis
  6. Heart failure (NYHA I - IV)
  7. Active bladder cancer or history of bladder cancer
  8. macroscopic haematuria of unidentified nature
  9. hypersensitivity to drug used (metformin, alogliptin, pioglitazone)
  10. breastfeeding

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

36 participants in 3 patient groups

metformin/alogliptin
Active Comparator group
Description:
metformin/alogliptin (850 mg/12.5 mg or 1000 mg/12.5 mg every 12 hours) for 12 months
Treatment:
Drug: Metformin / alogliptin Oral Product
metformin/pioglitazone
Active Comparator group
Description:
metformin/pioglitazone (850 mg/15 mg every 12 hours) for 12 months
Treatment:
Drug: Metformin / Pioglitazone Pill
triple therapy
Active Comparator group
Description:
metformin/pioglitazone (850 mg/15 mg every 12 hours)+alogliptin (12.5 mg every 12 hours) for 12 months
Treatment:
Drug: Metformin / alogliptin Oral Product
Drug: Metformin / Pioglitazone Pill
Drug: triple therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems